skip to main content

Listen

Read

Watch

Schedules

Programs

Events

Give

Account

Donation Heart Ribbon

Anglo-Swedish Drug Company Buying San Diego Biotech

Anglo-Swedish drug company AstraZeneca PLC is buying Ardea Biosciences, Inc., in a deal which values the U.S. biotech company at $1.26 billion.

AstraZeneca said Monday that it had agreed the takeover with San Diego-based Ardea, which is developing a treatment for elevated blood levels of uric acid in patients with gout.

AstraZeneca is paying $32 per share, representing a 54 percent premium on the closing share price last Friday.

The boards of both companies have approved the deal, and AstraZeneca says it has secured commitments from 30 percent of Ardea shareholders.

AstraZeneca says the deal is expected to close by the end of September.

Please stay on topic and be as concise as possible. Leaving a comment means you agree to our Community Discussion Rules. We like civilized discourse. We don't like spam, lying, profanity, harassment or personal attacks.

comments powered by Disqus